Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3245 SEK | +1.09% | -0.15% | +70.97% |
11/06 | Acarix Announces Enrollment of First Patient in Us-Based Clinical Workflow Evaluation Study | CI |
27/05 | Acarix AB Appoints Jeff Thomas as the New Head of US Sales, Effective June 1, 2024 | CI |
Sales 2024 * | 5.43Cr 51.92L 43Cr | Sales 2025 * | 18Cr 1.69Cr 140.86Cr | Capitalization | 31Cr 2.99Cr 249.18Cr |
---|---|---|---|---|---|
Net income 2024 * | -5.4Cr -51.64L -43Cr | Net income 2025 * | 20L 2L 1.6Cr | EV / Sales 2024 * | 5.68 x |
Net cash position 2024 * | 40L 4L 3.19Cr | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.77 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.96% |
Latest transcript on Acarix AB
1 day | +1.09% | ||
1 week | -0.15% | ||
Current month | +4.85% | ||
3 months | +28.26% | ||
6 months | +78.30% | ||
Current year | +70.97% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 60 | 01/07/01 | |
Director of Finance/CFO | 60 | 01/16/01 | |
Jennifer Matson
CTO | Chief Tech/Sci/R&D Officer | 47 | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 51 | 11/21/11 | |
Director/Board Member | 59 | 01/20/01 |
Date | Price | Change | Volume |
---|---|---|---|
18/24/18 | 0.3245 | +1.09% | 1 691 244 |
17/24/17 | 0.321 | -2.13% | 5,839,333 |
14/24/14 | 0.328 | +1.23% | 959,399 |
13/24/13 | 0.324 | -2.70% | 1,580,981 |
12/24/12 | 0.333 | +2.46% | 3,303,380 |
Delayed Quote Nasdaq Stockholm, June 18, 2024 at 07:09 pm IST
More quotes1st Jan change | Capi. | |
---|---|---|
+70.97% | 2.97Cr | |
-27.16% | 1.61TCr | |
-50.00% | 243.17Cr | |
+27.80% | 201.96Cr | |
-7.88% | 153.25Cr | |
+26.63% | 128.8Cr | |
-19.07% | 93Cr | |
-32.38% | 77Cr | |
+0.07% | 76Cr | |
-25.07% | 62Cr |
- Stock Market
- Equities
- ACARIX Stock